A stromal lysolipid–autotaxin signaling axis promotes pancreatic tumor progression FR Auciello, V Bulusu, C Oon, J Tait-Mulder, M Berry, S Bhattacharyya, ... Cancer discovery 9 (5), 617-627, 2019 | 255 | 2019 |
Modeling tumor phenotypes in vitro with three-dimensional bioprinting EM Langer, BL Allen-Petersen, SM King, ND Kendsersky, MA Turnidge, ... Cell reports 26 (3), 608-623. e6, 2019 | 227 | 2019 |
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer M Janghorban, AS Farrell, BL Allen-Petersen, C Pelz, CJ Daniel, J Oddo, ... Proceedings of the National Academy of Sciences 111 (25), 9157-9162, 2014 | 211 | 2014 |
Mission possible: advances in MYC therapeutic targeting in cancer BL Allen-Petersen, RC Sears BioDrugs 33 (5), 539-553, 2019 | 157 | 2019 |
Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer AS Farrell, B Allen-Petersen, CJ Daniel, X Wang, Z Wang, S Rodriguez, ... Molecular Cancer Research 12 (6), 924-939, 2014 | 157 | 2014 |
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance AS Farrell, MM Joly, BL Allen-Petersen, PJ Worth, C Lanciault, D Sauer, ... Nature communications 8 (1), 1728, 2017 | 100 | 2017 |
Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma BL Allen-Petersen, T Risom, Z Feng, Z Wang, ZP Jenny, MC Thoma, ... Cancer research 79 (1), 209-219, 2019 | 80 | 2019 |
Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer BL Allen-Petersen, CJ Carter, AM Ohm, ME Reyland Oncogene 33 (10), 1306-1315, 2014 | 67 | 2014 |
Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers CC Farrington, E Yuan, S Mazhar, S Izadmehr, L Hurst, BL Allen-Petersen, ... Journal of Biological Chemistry 295 (3), 757-770, 2020 | 56 | 2020 |
Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model SM King, DLG Nguyen, VA Gorgen, BR Shepherd, SC Presnell US Patent 9,983,195, 2018 | 29 | 2018 |
Loss of protein kinase C delta alters mammary gland development and apoptosis BL Allen-Petersen, MR Miller, MC Neville, SM Anderson, KI Nakayama, ... Cell Death & Disease 1 (1), e17-e17, 2010 | 27 | 2010 |
Three-dimensional bioprinted pancreatic tumor model R Sears, B Allen-Petersen, E Langer US Patent App. 14/820,307, 2016 | 22 | 2016 |
PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen SL Tinsley, BL Allen-Petersen Nar Cancer 4 (1), zcac002, 2022 | 15 | 2022 |
Microfluidics formulated liposomes of hypoxia activated prodrug for treatment of pancreatic cancer VM Shah, C Dorrell, A Al-Fatease, BL Allen-Petersen, Y Woo, Y Bortnyak, ... Pharmaceutics 14 (4), 713, 2022 | 10 | 2022 |
Sustained degradation of hyaluronic acid using an in situ forming implant K Hopkins, K Buno, N Romick, AC Freitas dos Santos, S Tinsley, ... PNAS nexus 1 (4), pgac193, 2022 | 3 | 2022 |
Engineered three-dimensional breast tissue, adipose tissue, and tumor disease model SM King, DLG Nguyen, VA Gorgen, BR Shepherd, SC Presnell, R Sears, ... | 3 | 2021 |
Abstract LT012: The prolyl isomerase PIN1 plays a critical role in fibroblast plasticity to impact pancreatic cancer EM Langer, IA English, KM Kresse, K MacPherson, BL Allen-Petersen, ... Cancer Research 81 (5_Supplement), LT012-LT012, 2021 | 1 | 2021 |
Three Dimensional Bioprinted Tumor Models for Drug Testing SC Presnell, SM King, DLG Nguyen, JO Minji, RS Pelz, B Allen-Petersen, ... US Patent App. 16/325,523, 2019 | 1 | 2019 |
The use of protein phosphatase 2A activators in combination therapies for pancreas cancer BL Allen-Petersen, RC Sears Oncotarget 10 (21), 2008, 2019 | 1 | 2019 |
Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark L Wang, A Pattnaik, SS Sahoo, EG Stone, Y Zhuang, A Benton, M Tajmul, ... Nature Communications 15 (1), 7288, 2024 | | 2024 |